Skip to content

Effect of Stellate Ganglion Block Combined with Intravenous Esketamine on Postoperative Analgesia and Negative Emotions in Breast Cancer Patients

Effect of Stellate Ganglion Block Combined with Intravenous Esketamine on Postoperative Analgesia and Negative Emotions in Breast Cancer Patients

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600123228
Enrollment
Unknown
Registered
2026-04-23
Start date
2024-11-29
Completion date
Unknown
Last updated
2026-04-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast cancer surgery

Interventions

Group N:Anesthesia induction was performed sequentially via intravenous injection of sufentanil 0.4 µg/kg, propofol 2 mg/kg, and cisatracurium besylate 0.2 mg/kg. After adequate oxygen administration
Group ES:On the basis of Group N , 0.3mg / kg of eszopiclone was given during the induction of anesthesia
Group SG:On the basis of Group ES , 5mL of 0.25% ropivacaine was injected into the right SGB under ultrasound guidance 10min before anesthesia induction

Sponsors

Hainan General Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1.Aged 18-70 years, with a body mass index (BMI) of 18-30 kg/m^2; 2.ASA classification I-II; 3.scheduled for elective unilateral radical or modified radical mastectomy with the ability to complete a two-day 3.postoperative follow-up; 4.capable of fully understanding and accurately assessing the numerical pain scale; 5.conscious, voluntarily signing an informed consent form, and cooperating with experimental testing.

Exclusion criteria

Exclusion criteria: 1.History of bilateral mastectomy or breast tumor resection; 2.poorly controlled hypertension, coronary heart disease, heart disease, increased intracranial pressure, etc.; 3.severe respiratory diseases such as chronic obstructive pulmonary disease or asthma; 4.contraindications for nerve block such as puncture site or systemic infection, coagulation disorders, peripheral neuropathy; 5.hyperthyroidism, goiter, history of thyroid surgery, or frequent coughing; 6.chronic pain, abuse or long-term use of anesthetics, sedatives, or analgesics; 7.allergy to local anesthetics or general anesthetics used during surgery; 8.severe hepatic or renal insufficiency, or neurological, psychiatric, or neuromuscular disorders; 9.women during menstruation, lactation, or pregnancy; 10.other conditions that may affect the study results.

Design outcomes

Primary

MeasureTime frame
sufentanil dosage;Numerical Rating Scale score;

Secondary

MeasureTime frame
Anxiety and depressive state;Sleep quality ;TNF-a;IL-6;

Countries

China

Contacts

Public ContactLiumei Cai;Duozhi Wu

Hainan General Hospital

164719211@qq.com+86 188 7698 2705

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: May 1, 2026